Storytelling Co – Lifestyle
Author:
Compass Therapeutics
Compass Therapeutics to Participate in Upcoming May Investor Events
May 12, 2026
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
May 5, 2026
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
April 27, 2026
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
April 24, 2026